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            Amendments from Version 1
We made minor changes to the article based on our reviewers’ 
comments.
We edited our hypothesis to fit the study design better. Previously 
we mentioned colonic short chain fatty acid (SCFA) production 
in our hypothesis. It was brought to our attention that we are 
not directly measuring colon samples. Therefore, we changed 
this to gut SCFA production which will be determined by breath 
hydrogen measurements and serum SCFA analysis.
It was pointed out that appetite regulation can be different 
between genders and oral contraceptives may have an impact 
on this regulation. As a result, we added that we will aim for 
a gender-balanced recruitment and note the use of any oral 
contraceptives.
It was highlighted that habitual diets of volunteers may impact 
gut microbiota. The cross-over design of the study allows 
each participant to act as their own controls. This will eliminate 
confounding factors like habitual dietary intake and gut 
microbiota profile. Current dietary assessment methods provide 
an inaccurate measure of dietary intake. As a result of these; we 
decided not to collect dietary intake data. However; we will be 
excluding participants following extreme diets such as vegan or 
vegetarian diets. We added this to our methods.
We also added that we will be analysing all dietary interventions 
for their fibre profiles as different types of fibres can have different 
impacts on gut microbiota and SCFA production.
Finally we added a new reference supporting the stimulation of 






Obesity is a chronic health problem that has reached epidemic 
proportions globally1. Obesity increases the risk of developing 
a range of non-communicable diseases including type 2 diabe-
tes, cardiovascular disease, certain cancers and osteoarthritis2. 
It has been projected that obesity rates could double by 2050, 
which would add £5.5 billion to the total annual expenses of the 
National Health Service (NHS)3. The Foresight report highlighted 
appetite regulation as a major target in the dietary treatment 
of obesity3. However, it is not yet fully understood how the 
gastrointestinal (GI) tract senses dietary content in order to 
suppress subsequent food intake. This knowledge could inform 
the development of foods or dietary regimes that increase fullness 
and prevent weight gain4.
The gastrointestinal tract
The GI tract is the largest endocrine organ in the body and is 
responsible for digesting and absorbing dietary components. 
The GI tract is also the host to a microbiota, which ferment 
undigested material. The GI tract senses changes in the luminal 
nutrient content and modulates neuronal and hormonal signals 
from the GI tract in order to help regulate appetite and food 
intake5. The anorexigenic gut hormones peptide YY (PYY) and 
glucagon-like peptide-1 (GLP-1), released from enteroendo-
crine cells (EEC)5, are examples of such GI signals secreted 
following a meal in a two-phase process. The first phase is thought 
to be mediated primarily by neural mechanisms and may help 
drive satiation (the sum of processes that cause meal termination). 
The second phase is thought to be mediated by direct nutrient 
sensing in the lower parts of the GI tract and to be an important 
long-term satiety signal. The peripheral administration of PYY 
or GLP-1 has previously been shown to reduce food consump-
tion in animal models and humans, highlighting the importance 
of these gut hormones6–10. It has therefore been suggested that 
the incorporation into the diet of foods that stimulate a greater 
gut hormone secretion could suppress appetite to a greater 
extent and therefore help control body weight in the long term.
Dietary fibre
There is an increasing amount of evidence to suggest that 
consumption of dietary fibre is beneficial to human health. Dietary 
fibre refers to carbohydrates that cannot be digested by mam-
malian enzymes, and thus remain in relatively intact form when 
they reach the caecum, where they are subsequently available for 
fermentation by the gut microbiota. Epidemiological evidence 
suggests that diets high in non-digestible fibres are associated 
with lower body weight gain in humans11,12. In addition, fer-
mentable fibres have been shown to protect against weight gain 
and fat mass development in rodents fed a high-fat diet13. Dietary 
fibre is thought to aid in weight management through a number 
of mechanisms including the promotion of satiation, increased 
GI transit time and stimulation of gut hormone secretion14. Short-
chain fatty acids, products of microbial fermentation, have also 
been shown to stimulate the secretion of GLP-1 and PYY15. 
Together, this evidence suggests that fibre may be beneficial in 
the management of obesity. 
Importance of the cellular structure of foods
The cellular structure of foods can also be an important deter-
minant of the subsequent impact of a food on appetite. In order 
for macronutrients within foods to be digested, they need to 
be in contact with digestive enzymes of the GI tract. In plant 
tissues, cell wall rupture can lead to a release of macronutri-
ents into the extracellular environment, or enzymes can diffuse 
through a permeable cell wall in order to digest the encapsulated 
macronutrients16. However, cell wall matrices or individual cell 
wall polysaccharides of plant foods can behave in a variety of 
ways during digestion. For example, some cell walls are highly 
impermeable and less susceptible to rupture, which leads to a 
reduction in the rate and extent of nutrient release and digestion. 
Thus, the cell walls of plants can behave as a physical barrier 
to digestion in the upper GI tract. The degree of domestic and 
industrial processing (e.g. milling, blending) of plant foods and 
ingredients also affects macronutrient bioaccessibility and diges-
tion by modifying the structural integrity of the plant tissue. 
The importance of cell wall integrity has previously been high-
lighted in determining the effect of plant foods on physiological 
functions. These studies reported that structurally intact plant 
tissues tend to be digested to a lesser extent and at a slower 
rate, which attenuated the postprandial rise in glycaemia and/or 
lipaemia17–19, and may also trigger the release of lower concen-
trations of anorexigenic gut hormones within the small intes-
tine, compared to foods in which the nutrients are bioaccessible. 
However, upon reaching the colon from the distal ileum, 
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undigested plant material serves as a substrate for microbial fer-
mentation, which leads to the production of SCFA and trig-
gers the release of anorexigenic gut hormones. This process 
is thought to result in a more long-term satiety signal following 
the consumption of minimally processed plant-based foods.
Study rationale
Within the GI tract, the colon contains the highest density of 
EEC20. These cells express a large array of G protein coupled 
receptors (GPCRs) that sense nutrients and metabolites in the 
colonic lumen21. This gives the colon the ability to regulate 
appetite and the GI tract in response to the nutrient environment 
in the colonic lumen. A major component of the digesta reach-
ing the colon is carbohydrate, which is a major fuel source of 
the gut microbiota22. The flow of carbohydrate into the colon 
from the distal ileum can radically change populations of bac-
teria in the colon and metabolites they produce, particularly 
SCFAs22. However, very little is known about the type and 
amount of carbohydrate present in the ileum as well as the com-
position of the ileum microbiota in humans. Most of our current 
understanding of carbohydrate that is not absorbed by the small 
intestine comes from ileostomy models23. These models may 
not reflect the physiology of an intact GI tract, as the gut alters 
following the surgery. In the present study we will use an ileum 
intubation method in healthy humans, which will allow us to 
gain a ‘real-time’ perspective on how the actual ileum content 
changes in response to different diets and the subsequent effect 
on measures of appetite and gut hormone secretion. We will also 
conduct an in vitro study in order to understand how ileum con-
tent affects the colonic gut microbiota and the production of 
SCFA in the colon, as this is important in determining how 
dietary carbohydrate drives colonic gut hormone release.
Study objectives
Hypothesis
We hypothesise that the consumption of minimally-processed 
high-fibre foods will result in more intact cellular structures 
and carbohydrate reaching the distal ileum and thus increasing 
SCFA production and PYY and GLP-1 release.
Objectives
There are a number of objectives to the present study: to identify 
the impact of dietary carbohydrate on (1) the forms and levels 
of carbohydrates in, and (2) the microbiological profile of, the 
ileum, and to (3) to determine whether the carbohydrate content 
of the ileum relates to appetite responses and gut hormone release.
Primary and secondary outcome measures
The co-primary outcome measures for this study are:
1.   Metabolic profiling of ileal samples
2.   Microbiological profiling of ileal samples
The secondary outcome measures include:
1.    Microscopy of ileal samples for plant structures, cellular 
structures and starch granules
2.   Metabolic and hormonal profiling of blood samples
3.   Metabolic and microbiological profiling of faecal samples
4.   Subjective appetite measurements
5.   Breath H2 concentrations
6.    Ileum samples for the inoculation of an in vitro continuous 
fermentation model
Protocol
This study will be a randomised crossover study consisting of 
three separate 4-day inpatient study visits at the National Institute 
for Health Research (NIHR) Imperial Clinical Research Facility 
(CRF), Hammersmith Hospital, London, United Kingdom.
Health screening
Healthy humans will be recruited using existing healthy vol-
unteer databases (e.g. the Healthy Volunteer Panel at the NIHR 
Imperial CRF) and by advertisement in public buildings, on 
the internet and social media. Participants who express an inter-
est in taking part in the study will be provided with the Patient 
Information Sheet (PIS). Following an initial telephone screen-
ing, potential participants will be invited to attend a health 
screening visit at the NIHR Imperial CRF in order to further 
assess their eligibility and provide written, informed consent to 
a member of the study team. The consent form and participant 
information sheet are available on Figshare24. During health 
screening, the study protocol and the risks and benefits of 
participating will be explained in full and any questions that the 
participant may have will be answered. Participants will be asked 
questions about their medical history, anthropometric meas-
urements will be collected, blood pressure (BP) will be meas-
ured, an echocardiogram (ECG) will be performed and a blood 
sample taken. The collected blood sample (1 x 20 ml) will be 
used to assess HbA1c, full blood count, liver function, renal 
function and blood lipids. A pregnancy test will be performed on 
women of childbearing age. Use of contraceptives will be noted. 
Inclusion and exclusion criteria will be assessed as described.
Study population
Healthy humans aged between 18–65 years (inclusive) with 
a body mass index (BMI) of 18.5-30 kg/m2 will be recruited 
for this study. A gender-balanced recruitment will be aimed. 
They must also show a willingness and ability to give written 
informed consent and to understand, to participate and to com-
ply with the study requirements. Exclusion criteria includes: 
abnormal echocardiograph (ECG), screening blood results 
outside of normal reference values, weight change of ≥5kg in the 
preceding 2 months, current smokers, history of substance abuse 
and/or excess alcohol intake in the last 2 years, pregnancy, diabe-
tes, cardiovascular disease, cancer, gastrointestinal disease, kidney 
disease, liver disease, pancreatitis, started new medication within 
the last 3 months likely to interfere with energy metabolism/ 
appetite regulation/hormonal balance, antibiotic use within the last 
months, participation in a research study in the 12 week period 
prior to entering this study, any blood donation within the 12 week 
period prior to entering this study, vegan or vegetarian diets.
Randomisation
Following the health screening, eligible participants will be 
randomised into the study. Randomisation will be performed by 
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an independent internet and telephone randomisation company 
(sealedenvelope.com). Due to the different physical appearance 
of the diets, participants will not be blinded.
Sample size
We aim to recruit 15 subjects. This is a pilot study in a new 
area of research and therefore a formal power calculation is not 
possible. However, a recent study in ileostomy patients inves-
tigating differences in the carbohydrate output in ileal effluent 
depending on the quality of carbohydrate consumed was able to 
detect significant differences between outcome measures in a 
similar number of subjects (n=9)18.
Dietary intervention
Dietary calculations. All three diets are tailored to meet the 
energy requirements (TEE, total energy expenditure) of each 
participant. Using the participant’s weight and age at screening, 
Schofield equations will be used to calculate each participant’s 
basal metabolic rate (BMR) as shown in Table 1. This will then 
be multiplied by 238.85 to convert MJ/d to kcal/d and then by 
1.2 to account for their low physical activity level (PAL) while 
being inpatients at the CRF.
Dietary overview. During the 3 separate study visits, volunteers 
will be provided with diets differing in carbohydrate quality, 
which have been designed using DietPlan 6 software. In a 
randomised order, volunteers will receive:
•    Diet 1 (low fibre (LF)-refined): This diet contains highly 
refined and processed carbohydrate. Foods are low in fibre 
and intact cell structures.
•    Diet 2 (high fibre (HF)-whole): This diet is high in fibre 
providing a high intake of intact cellular structures. Foods 
have resistant cell structures such as beans, nuts, fruit and 
vegetables.
•    Diet 3 (HF-disrupted): This diet is also high in fibre but 
with disrupted cellular structures. It is the same as the 
HF-whole diet, but foods will be milled or blended to 
disrupt the cellular structure.
All the diets have a similar macronutrient content (55% energy 
from carbohydrate, 30% energy from fat, 15% energy from 
protein). However, the quality of carbohydrate present is signifi-
cantly different. For example, the HF-whole and HF-disrupted 
diets contain 46.5 g and 47.7 g dietary fibre/2000 kcal, respec-
tively, while the LF-refined diet contains only 16.3 g dietary 
fibre/2000 kcal. Diets will also be analysed for their dietary fibre 
profiles.
Breakfast, lunch and dinner will each provide 30% of the par-
ticipant’s prescribed caloric intake and an evening snack will 
provide the final 10%. The dietary plan for each diet is outlined 
in Table 2. All food provided to the participants will be prepared 
by the study team in the CRF Diet Kitchen according to food 
hygiene/food safety standards.
Diet preparation. For the LF-refined diet, breakfast will be 
prepared the night before serving but the bread will be toasted 
and the milk will be added to the cornflakes immediately before 
serving. The meals served at 13:00 and 17:00 will be ready 
meals, which will be cooked in the microwave according to the 
manufacturer’s instructions and the required portion will be 
weighed out before serving.
For the HF-whole diet, the breakfast will be prepared the day before 
serving and the oats will be soaked in milk from approximately 
16:30 the evening before. The lunch will be prepared in the hour 
before serving; the apples will be cut into chunks that are easier 
to eat and the soup will be weighed out and microwaved just 
before serving. The dinner will be prepared in the hour before 
serving. The potatoes will be boiled for 20 min and the peas 
microwaved according to the manufacturer’s instructions. Both 
will be drained and weighed after cooking. All other foods 
will be served cold. The carrot, beetroot and tomatoes will be 
cut up into smaller pieces that are easier to eat. The evening 
snack will be prepared at dinner-time.
For the HF-disrupted diet, the oats will be blended in advance 
into a flour-like consistency. The rye bread and humous will 
be made in advance in-house, frozen and defrosted as needed. 
The breakfast will be prepared the day before serving. The 
oranges will be blended to a smoothie. The oats will be soaked in 
milk from approximately 16:30 the evening before and heated 
in the microwave immediately before serving. The lunch will be 
Table 1. Formula for calculating total energy expenditure (TEE) (kcal/day) using the Schofield equations 
and physical activity level correction.
Gender Age range (y) Regression formula for BMR (MJ/d) TEE calculation (kcal/d)
Male 18–29 0.063 x weight (kg) + 2.896 * 238.85 (To convert MJ to kcal) * 1.2 (PAL) 
30–59 0.048 x weight (kg) + 3.653
60–74 0.0499 x weight (kg) + 2.930
Female 18–29 0.062 x weight (kg) + 2.036
30–59 0.034 x weight (kg) + 3.538
60–74 0.0386 x weight (kg) + 2.875
BMR, basal metabolic rate.
PAL, physical activity level.
TEE, total energy expenditure.
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Table 2. Dietary plan for intervention diets.
Meal Time LF-refined HF-whole HF-disrupted % E provided
Breakfast 9 am Cornflakes cereal Jumbo oats Finely milled oats, blended 30
Whole milk Whole milk Whole milk
White bread, toasted German style rye bread Rye bread made with wholemeal flour
Margarine Margarine Margarine
Full fat natural yoghurt Full fat natural yoghurt Full fat natural yoghurt
Oranges Oranges, blended
Lunch 1 pm Beef lasagne Carrot and butterbean soup 
(tinned)
Carrot and butterbean soup (tinned), blended 30
Coca Cola German style rye bread Rye bread made with wholemeal flour
Margarine Margarine
Apples Apples, blended
Plain peanuts Plain peanut butter
Dinner 5 pm Shepherd’s pie Chicken breast (pre-packed) Chicken breast (pre-packed) 30
Coca Cola Boiled new potatoes Boiled new potatoes, blended
Wine gum sweets Raw carrot Boiled carrot, blended
Peas (tinned) Peas (tinned), blended
Beetroot (pre-packed) Beetroot (pre-packed), blended
Cherry tomatoes Cherry tomatoes, blended
Chickpeas* (tinned) with 
lemon juice, olive oil, parsley, 
mint, black pepper, salt
Chickpea humus* (Chickpeas (tinned) with 
lemon juice, olive oil, parsley, mint, black 
pepper, salt, which are blended into a humus)






*Chickpea and chickpea humus recipes will be energy matched. E, energy, HF, high fibre; LF, low fibre.
prepared in the hour before serving. The apples will be blended 
to a puree. The can of soup will be blended, the required portion 
will be weighed out and microwaved just before serving. The 
dinner will be prepared in the hour before serving. The beetroot 
and tomatoes will be blended to a smoothie. The potatoes and 
carrots will be boiled for 20 min and the peas will be 
microwaved according to the manufacturer’s instructions. The 
vegetables will then be drained, blended and weighed. The 
potato, carrot and peas will then be re-heated in the microwave 
to comply with food safety standards. All other foods will be 
served cold. The snack is prepared at dinner-time and the 
bananas and oranges will be blended.
All foods that are heated or cooked by the study team will be 
temperature probed before serving.
Study visit protocol
An overview of the study visit protocol is outlined in Figure 1. 
Participants will attend their first study visit within 12 weeks 
of their screening visit. There will be a minimum wash out 
period of 7 days between study visits.
Day 1: Nasoenteric tube insertion. Participants will be asked 
to arrive at the Imaging Department in Charing Cross Hospital, 
London, having fasted overnight and having avoided intense 
exercise, caffeine and alcohol the day before their study visit. 
Females of child-bearing age will be asked to provide a urine 
specimen in order to perform a pregnancy test. A custom-made 
nasoenteric tube (Figure 2) will then inserted through the nose. 
Once it has passed the stomach and the first part of the small 
intestine, the balloon at the terminal end will be inflated to 
approximately 6 ml and will be used to carry the tube through 
the small intestine by peristalsis. The tube position will be 
confirmed by fluoroscopy throughout the tube insertion process. 
Dilute barium sulphate may also be administered in order to 
help confirm the positioning. Once the tube has reached the 
terminal ileum, the balloon will be deflated and the tube will be 
restrained from additional movement for the rest of the 4-day 
visit. Participants will be provided with food and drinks 
during the tube insertion process. However, the food pro-
vided will not be standardised to allow for flexibility to aid tube 
insertion. Following the tube insertion, participants will travel 
back to the NIHR Imperial CRF, Hammersmith Hospital, accom-
panied by a trained medical professional. The final position 
of the tube will be recorded in the participant’s notes.
Day 1 – Start of dietary intervention. Participants will be fed 
one of the three diets over the 4-day study period according 
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Figure 2. Nasoenteric tube design. Published with permission from MUI Scientific.
Figure 1. Study visit overview. Abbreviations: BL, baseline; CX, Charing Cross Hospital; HH, Hammersmith Hospital; Pt, patient; VAS, visual 
analogue scale.
to their randomisation. The dietary intervention will start 
with dinner on Day 1 and end with lunch on Day 4. Meals will 
be provided at set times; breakfast at 09:00, lunch at 13:00, 
dinner at 17:00 and an evening snack at 21:00. During their 
stay, participants will be asked to eat all of the food that is pro-
vided and to not eat any other food including chewing gum. 
Participants will have free access to water, except for during 
sampling periods on Day 3 and 4 where water will be limited. 
Participants will not be allowed to leave the CRF during their 
visit but will have access to WiFi and TV. Participants will be 
asked to collect a stool sample each time they pass stool during 
their inpatient stay for metabolomic and microbiological analysis.
Day 2 – Acclimatisation day. Day 2 will allow participants to 
acclimatise to their new diet and environment. Meals will be 
provided at set meal times and participants will have free access 
to water. The only samples collected on Day 2 will be stool 
samples.
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Day 3 – Ileal sampling. On day 3, ileal samples will be 
collected via the nasoenteric tube for metabolomic and 
microbiological analysis. For the 30 minutes before breakfast, 
the participant’s water jug will be removed. Two baseline ileal 
samples will be collected >10 min apart. Breakfast will be 
served at 9:00 am (±10 min) with 500 ml water. The time at 
which each participant starts eating breakfast will be consid-
ered to be 0 min. Further ileal samples will be collected every 
60 min for 480 min. Lunch will be served directly after the 
240 min sample with 500 ml water. Dinner will be served at 
17:00, after the 480 min sample and participants will have free 
access to water for the rest of the day.
Day 4 – Ileal and blood sampling. On the morning of day 4, 
participants will have an intravenous cannula inserted to allow 
for blood sampling and body composition will be assessed by 
bio-impedance analysis. For the 30 minutes before breakfast, 
the participant’s water jug will be removed, as on day 3. Two 
baseline samples will be collected >10 min apart before 
breakfast. At each timepoint, subjective feelings of appetite 
(‘how hungry/full do you feel?’) and mood (‘how nauseous do 
you feel?’) will be collected using a series of 100 mm visual 
analogue scales (VAS). The left extremity of the VAS is labelled 
with ‘not at all’ and the right-hand extremity is labelled with 
‘extremely’. Participants will be asked to draw a vertical line on 
the VAS depending on how intensely they are experiencing each 
feeling. Baseline breath H2 measurements will be collected in 
real-time using a handheld monitor (Gastro+ Gastrolyser Breath 
Hydrogen Monitor, Bedfont Scientific) and will be used as a 
marker of intestinal fermentation25. Baseline blood samples will 
be collected to assess blood hormones and metabolites and ileal 
samples will be collected via the nasoenteric tube as on Day 3. 
Ileal samples will be collected across both Day 3 and 4 in order 
to gain a full understanding of the dynamic change of the ileum 
environment over the study period. Once both baseline samples 
have been collected, breakfast will be served at 9:00 am 
(±10 min) with 500 ml water. The time at which the partici-
pant starts eating breakfast will be considered to be 0 min. 
Further samples will be collected every 60 min for 480 min. 
Lunch will be served directly after the 240 min sample with 
500 ml water. Following the final sample at 480 min, the 
cannula and nasoenteric tube will be removed and participants 
will be discharged.
Sample preparation
Stool samples. Stool samples will be frozen at -80°C imme-
diately following collection and the time of collection will be 
recorded.
Ileal samples. In order to collect ileal samples, the aspiration 
channel of the tube will first be flushed with a volume of 
water that is equal to the deadspace leading to the lumen. The 
air channel will be opened and the volume of water that the 
tube was flushed with will be taken back using a 50 ml syringe. 
Once the flush has been collected, the aspiration channel will be 
clamped using a medical clamp and the flush will be discarded. 
Up to 5 ml ileal sample will be collected at each sampling 
timepoint. Samples will be put on ice immediately following 
collection and frozen at -80°C. Following sampling, the aspira-
tion channel of the tube will be flushed with a volume of water 
that is equal to the deadspace and both the aspiration and air 
channels will be closed until the next sample.
Blood samples. A total of 10 ml blood will be collected at each 
time point and aliquoted into vacutainers: 1 ml blood will be 
added to a BD Fluoride Ethylenediaminetetraacetic acid (EDTA) 
Vacutainer; 2 ml blood will be added to a BD Lithium Heparin 
Vacutainer containing 20 μl/ml whole blood Aprotinin pancre-
atic protease inhibitor (Nordic Pharma UK Ltd, Reading, UK), 
2ml blood will be added to a BD Lithium Heparin Vacutainer 
and 5 ml blood will be added to a BD Serum SST Vacutainer. 
Plasma tubes will be centrifuged immediately at 2,500 relative 
centrifugal force (RCF) for 10 min at 4°C. Serum tubes will be 
allowed to clot before centrifugation. Resulting plasma and 
serum will be separated and frozen at -80°C until analysis.
Sample analysis
Samples will be analysed upon completion of the study. Meta-
bolic and microbiological profiling of ileal and faecal samples 
will be performed using 1H-NMR spectroscopy and 16S sequenc-
ing, respectively. The metabolic and hormonal profiling of blood 
samples will be assessed using 1H-NMR spectroscopy, radioim-
munoassays, Ultraperformance Liquid Chromatograpy coupled 
to Mass Spectrometry (UPLC-MS) and Gas Chromatography 
coupled to Mass Spectrometry (GC-MS). Subjective appe-
tite will be assessed using visual analogue scales (VAS) and 
breath H2 will be measured in real-time using a handheld 
gastrolyser.
In-vitro continuous fermentation model system
A one-stage continuous fermentation model system will be 
established using ileal samples from the human study to moni-
tor in vitro the effect of carbohydrate quality on ileal microbiota 
composition and their subsequent metabolites. The system will 
be adapted from the three-stage colonic model described by 
Gibson et al.26. Ileal samples will be collected via a nasoenteric 
tube (Figure 2) as previously described and anaerobically 
transferred into hungate tubes, which will then be used to 
inoculate the in vitro system. Samples will be obtained from the 
system at baseline (t=0) and 24 hours after (t=24).
The diets from the human study will then be tested in the 
in vitro system. Diets will be digested by an in vitro simulation 
of upper gut digestion as per Mills et al.27. The remaining prod-
ucts will be dialysed using a membrane of 100–200 Dalton cut 
off (Biotech CE Dialysis Tubing, Spectrum Europe, Netherlands). 
The products will be freeze-dried before their addition to the 
in vitro system. Samples will be obtained from the system 
24 hours after the addition of the diets (t=48) to measure 
main bacterial groups using fluorescent in situ hybridisation 
(FISH) and for microbial produced metabolites using 1H-NMR 
spectroscopy.
Page 8 of 16
F1000Research 2019, 8:258 Last updated: 11 DEC 2019
Data management and dissemination
Data management
Participants will be given an anonymised personal study code 
number once randomised, which will be used throughout the 
study and in the analysis of data. The study codes will be kept 
on departmental databases. All personal data will be stored in 
locked filing cabinets in the Section of Investigative Medicine, 
Imperial College London. Only members of the Section of 
Investigative Medicine will have access to these. The Princi-
pal Investigator and the study team will have access to the final 
trial dataset.
Statistical methods
A formal data analysis plan will be drawn up upon completion 
of the study. However, assuming the data is parametric and con-
forms to similar studies we have conducted, we would expect 
our outcome measures to be analysed using a variety of sta-
tistical methods. These will include parametric statistics and 
multivariate analysis using pattern recognition techniques 
such as principal component analyses (PCA) and partial least 
squares discriminant analysis (PLS-DA) and non-metric multi-
dimensional scaling (NMDS) plots, using a number of statistical 
packages including SPSS, MATLAB and R.
Data monitoring
As this is a pilot study, there are too few participants to have a 
data monitoring committee.
Trial sponsor
Imperial College is the main research sponsor for this study.
Dissemination of results
Once data analysis is complete, participants will receive a lay 
summary of the study’s findings. In addition, the results of the 
study will be presented at scientific meetings and conferences, 
and published in relevant high-impact journals. Research papers 
will be written by the study team. Authors will be included 
according to the International Committee of Medical Journal 
Editors (ICMJE) Recommendations. An anonymised dataset 
will be made available to the scientific community.
Ethical approval
This study has been approved by the London – Bloomsbury 
Research Ethics Committee (REC) and Health Research Author-
ity (HRA; REC Reference Number: 17/LO/0354). This study 
will be conducted in accordance with the recommendations 
for physicians involved in research on human subjects adopted 
by the 18th World Medical Assembly, Helsinki 1964 and later 
revisions. Any substantial amendments made to the protocol, 
PIS or consent form will be submitted to the REC and HRA. 
Once these changes have been approved, these modifcations 
will be explained to participants and implemented with their 
consent.
Participants will have the choice during the consent process 
to agree to their samples being stored and used for future 
analyses. Samples will be kept in the Section of Investigative 
Medicine and will only be used for other research purposes that 
have been ethically approved.
Adverse events
Any significant adverse event as assessed by the researchers 
will halt the study and the research ethics committee and spon-
sor will be informed as per standard protocol. All adverse events 
will be recorded and investigators will review each adverse 
event as it arises.
Indemnity
Imperial College London holds negligent harm and non-negligent 
harm insurance policies, which apply to this study.
Discussion
The maintenance of body weight throughout life is impor-
tant for metabolic homeostasis. Over the last 15 years, both 
epidemiological and experimental evidence have highlighted the 
importance of carbohydrate fermentation within the gut to appe-
tite regulation. However, our current investigative tools are not 
capable of characterising the complex signalling that mediates 
these effects in the gut. In the current study, we will investigate 
how the quality of dietary carbohydrate consumed affects the 
form and type of carbohydrate in the ileum. This will allow us 
to gain a deeper understanding of the composition of the digesta 
reaching the colon from the ileum following such diets. In addi-
tion, we will determine how this subsequently affects subjective 
appetite measures and gut hormone secretion. We will use an 
in vitro model, inoculated with ileal fluid, to provide a deeper 
understanding of how ileum contents, following diets differing 
in carbohydrate quality, affects the colonic gut microbiota and 
the production of SCFAs in the colon. This is important in 
identifying how dietary carbohydrate drives colonic gut 
hormone release and is critical in understanding the relationship 
between the colon and the maintenance of energy homeostasis. 
This knowledge may facilitate the development of food products 
designed for body weight maintenance.
Study progress
The first study visit was completed in October 2017. Eight 
participants have successfully completed the study so far.
Data availability
Underlying data
No underlying data are associated with this article.
Extended data
Figshare: A study protocol for a randomised crossover study 
evaluating the effect of diets differing in carbohydrate quality 
on ileal content and appetite regulation in healthy humans. 
https://doi.org/10.6084/m9.figshare.7752131.v124.
This project contains the following extended data:
•    Participant Information Sheet - Version 5 – 111017.doc 
(information sheet for research participants)
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•    Consent Form - Version 1 - 060217.doc (consent form 
given to each participant)
Reporting guidelines
Figshare: SPIRIT checklist for “A study protocol for a randomised 
crossover study evaluating the effect of diets differing in carbo-
hydrate quality on ileal content and appetite regulation in healthy 
humans”. https://doi.org/10.6084/m9.figshare.7752131.v124.
Data are available under the terms of the Creative Commons 
Attribution 4.0 International license (CC-BY 4.0).
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